Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug respo...

Full description

Saved in:

Bibliographic Details
Published in:	Supportive care in cancer Vol. 27; no. 10; pp. 3729 - 3737
Main Authors:	Chan, Alexandre, Hertz, Daniel L., Morales, Manuel, Adams, Elizabeth J., Gordon, Sharon, Tan, Chia Jie, Staff, Nathan P., Kamath, Jayesh, Oh, Jeong, Shinde, Shivani, Pon, Doreen, Dixit, Niharkia, D’Olimpio, James, Dumitrescu, Cristina, Gobbo, Margherita, Kober, Kord, Mayo, Samantha, Pang, Linda, Subbiah, Ishwaria, Beutler, Andreas S., Peters, Katherine B., Loprinzi, Charles, Lustberg, Maryam B.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-10-2019 Springer Springer Nature B.V
Subjects:	Antineoplastic Agents - adverse effects Biomarkers Bortezomib - adverse effects Cancer Chemotherapy Clopidogrel Complications and side effects Dasatinib Genetic Predisposition to Disease - genetics Genetics Humans Inhibitor drugs Medical colleges Medicine Medicine & Public Health Molecular biology Neurotoxicity Syndromes - drug therapy Nilotinib Nursing Nursing Research Oncology Pain Medicine Patient compliance Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - genetics Peripheral neuropathy Pharmacology Rehabilitation Medicine Review Article Side effects Taxoids - adverse effects Vinca Alkaloids - adverse effects Vincristine Chemotherapy-induced peripheral neuropathy CIPN Neuropathy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.
ISSN:	0941-4355 1433-7339
DOI:	10.1007/s00520-019-04987-8